Published in final edited form as:

Cell Mol Life Sci. 2010 November ; 67(21): 3621–3631. doi:10.1007/s00018-010-0488-2.

Small Molecule Inhibitors of DNA Repair Nuclease Activities of APE1

David M. Wilson III^{1,*} and Anton Simeonov²

¹ Laboratory of Molecular Gerontology, Biomedical Research Center, National Institute on Aging, NIH, IRP, 251 Bayview Boulevard, Baltimore, MD 21224

² NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892-3370

Abstract

APE1 is a multifunctional protein that possesses several nuclease activities, including the ability to incise at apurinic/apyrimidinic (AP) sites in DNA or RNA, to excise 3'-blocking termini from DNA ends, and to cleave at certain oxidized base lesions in DNA. Pre-clinical and clinical data indicate a role for APE1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs, particularly monofunctional alkylators and antimetabolites. In an effort to improve the efficacy of therapeutic compounds, such as temozolomide, groups have begun to develop high-throughput screening assays and to identify small molecule inhibitors against APE1 repair nuclease activities. It is envisioned that such inhibitors will be used in combinatorial treatment paradigms to enhance the efficacy of DNA-interactive drugs that introduce relevant cytotoxic DNA lesions. In this review, we summarize the current state of the efforts to design potent and selective inhibitors against APE1 AP site incision activity.

Keywords

APE1/APEX1/REF-1; abasic endonuclease; DNA damage; base excision DNA repair; inhibitor; cancer treatment

Introduction

It was not until after the elucidation of the DNA structure by Watson and Crick that the scientific community began to fully recognize the vulnerability of genetic material to spontaneous decomposition or reactions with exogenous or endogenous physical and chemical agents [1]. This realization prompted interest in the prospect that organisms had evolved corrective systems to preserve genome integrity to avert deleterious outcomes such as mutagenesis and cell death. The first evidence for the existence of "DNA repair" was described by Kelner [2] and Dulbecco [3], who discovered independently, although not deliberately, that the variability in survival of cells following ultraviolet irradiation was due to differences in exposure to visible light after treatment. It was later uncovered that there exists a light-dependent photoreactivation process (catalyzed by the enzyme photolyase) that removes cytotoxic photodamage (i.e. cyclobutane pyrimidine dimers) produced within the genome [4].

As the DNA repair field began to emerge, it was soon recognized that the most common forms of DNA damage are likely those that arise as spontaneous hydrolytic products due to the

*Send Correspondence To: Ph: (410) 558 8153, Fx: (410) 558 8157, wilsonda@mail.nih.gov.

intrinsic instability of nucleic acid or as products of attack by endogenous chemical species, most notably reactive oxygen or nitrogen species formed during mitochondrial respiration [5]. One of the most frequent forms of DNA damage includes the apurinic/aprimidinic (AP) site, which has been estimated to arise at a rate of roughly 10,000 times per mammalian genome per day. AP sites, which pose a mutagenic and cytotoxic challenge to the cell [6], are products of both spontaneous and damage-induced base loss, and are also intermediates generated during the base excision DNA repair (BER) response (Figure 1). In the early 1980s, two groups described a human enzyme from placenta and HeLa cell extracts that possessed the ability to incise at AP sites introduced into plasmid DNA by heat and acid [7,8]. Almost ten years later, the gene encoding the predominant human AP endonuclease was cloned and named *APE* [9], *HAP1* [10] or *APEX* [11], now more commonly referred to as *APE1* or *APEX1*.

Since the discovery of the *APE1* gene, significant research has been performed by a number of laboratories to characterize the structure-function mechanism and the biological roles of the protein (see reviews such as [12–16]). More recently, the decades of information gathered on *APE1*, as well as the mounting evidence that DNA repair is a logical target for improving anticancer treatment paradigms involving DNA-interactive cytotoxins [17], has spurred investigators to initiate screens for small molecule inhibitors of DNA repair proteins in general and the *APE1* nuclease in particular. This review summarizes the various nuclease activities of *APE1*, the principle behind the reported high-throughput screening assays, and the current picture of the identified endonuclease inhibitors.

Nuclease Activities of *APE1*

APE1 is a ~35,500 Da protein comprised of a four-layered α/β -sandwich core domain (Figure 2), with a disordered N-terminal extension (not seen in crystal structures to date). The globular core exhibits structural similarity to the divalent cation-dependent phosphoesterase superfamily of proteins, which includes nucleases, inositol (polyphosphate) and possibly protein phosphatases, and sphingomyelinases, and encompasses the endonuclease portion of *APE1* [12,18]. The unique N-terminal segment of ~50 amino acids appears to have been acquired via divergent evolution, and imparts several additional features to the mammalian protein, including nuclear targeting, transcriptional regulatory roles, and its so-called redox (or REF-1) function, which are reviewed in the accompanying articles of this Special Issue. The N-terminal portion of human *APE1* may also serve as a docking platform for certain protein interactions (see for example [19–21]).

APE1 executes a Mg^{2+} -promoted hydrolytic catalytic reaction that severs the phosphodiester bond to facilitate the BER response (Figure 3, left). While the name “*APE1*” stems from the ability of the protein to incise at AP sites as an endonuclease, the enzyme was described early as a protein with phosphodiesterase activity for 3'-blocking groups (e.g. 3'-phosphoglycolate ester) in DNA (Figure 3, right) [22]. In this capacity, *APE1* has the ability to excise 3'-obstructive termini, which would normally be refractory to DNA repair synthesis and thus potentially genotoxic, to generate the needed 3'-hydroxyl priming group. In addition, *APE1* has a weak (typically ≥ 100 -fold less efficient than its AP endonuclease activity), albeit measurable, 3' to 5' exonuclease function that is influenced by reaction conditions, the configuration of the DNA substrate (i.e. sequence context and precise location of the 3'-target nucleotide), and the chemical composition of the terminal nucleotide [23–29]. For instance, *APE1* exhibits a more robust excision activity on 3' nucleotides in a single-strand break context than at a double-strand break end, and efficiently removes, both *in vitro* and *in vivo*, the chain-terminating nucleoside analog troxacitabine, which is currently in clinical trials for the treatment of refractory acute myelogenous leukemia and various solid tumors. *APE1* also possesses less expected nuclease activities, such as an ability to incise 5' to oxidative base modifications, e.g. 5,6-dihydro-2'-deoxyuridine, 5,6-dihydrothymidine, 5-hydroxy-2'-

deoxyuridine, alpha-2'-deoxyadenosine and alpha-thymidine adducts, in a process known as nucleotide incision repair (NIR) [30].

Besides operating on DNA (see summary of APE1 nuclease substrates in Figure 3), recent studies have found that APE1 can cleave at abasic sites or at certain sequence contexts in RNA molecules [21,31,32]. The former activity has been suggested to play a role in “cleansing” the RNA pool by removing damaged RNA templates, while the latter function may operate to regulate gene expression. Although the screening assays described next have focused on the identification of inhibitors of the AP site incision activity of APE1, it is likely that any inhibitor identified would inactivate all of the aforementioned nuclease functions. This conclusion stems largely from the fact that APE1 maintains a single nuclease active site, which is in part comprised of the critical, conserved amino acids E96, D210 and H309 (Figure 3) [12,13]. However, it would be of interest to design inhibitor compounds, if feasible, that exhibit selective inactivation of a particular nuclease function. It is also possible that some inhibitors might be allosteric and as such might inhibit the various nuclease activities differentially or may exert effects on the redox or regulatory functions of this protein as well.

Screening Strategy for Inhibitors of APE1 Incision Activity

The strategy for high-throughput screening for inhibitors of APE1 AP site incision activity was first described by Madhusudan *et al.* [33], who designed a fluorescence-based (molecular beacon) assay system. In particular, a 5'-fluorescein labeled, AP site-containing DNA strand was annealed to a 3'-dabcyl labeled complementary oligonucleotide (Figure 4). Positioning of the fluorophore and quench opposite one another resulted in a significantly reduced fluorescence relative to the 5'-fluorescein single strand oligonucleotide alone. Since the AP site was located in close proximity to the 5'-terminal end, following APE1 cleavage, the short 5'-fluorescein-containing DNA product was spontaneously released from the duplex, resulting in increased fluorescence readout. Thus, inhibitors are revealed by a reduced (or background) fluorescence in high-throughput multi-well screens.

Additional groups have more recently described variations of this strategy, employing different sequence contexts (to optimize the signal to background ratio) or fluorogenic substrates (i.e. TAMRA-labeled, to shift the signal detection to a longer wavelength, thereby minimizing the interfering effect of compound autofluorescence), although each screening method operates under the same guiding principles (see for instance [34]). Indeed, the use of fluorogenic screening assays has gained broad support, and such strategies have been applied to a number of nucleic acid metabolizing enzymes, including DNA polymerases [35], ligases [36] and helicases [37]. Furthermore, recent advances in technology have allowed for the execution of APE1 inhibitor screens in very low reaction volumes (e.g. 4 uL in 1536-well plates) and collection of data in real-time kinetic mode [34]. Recently, an alternative assay that monitors APE1 incision activity with potential high-throughput applicability was designed that employs an instrument for spectral cross-talk-free dual-color fluorescence cross-correlation spectroscopy, using a double-stranded DNA substrate labeled with Cy3 and IRD800 [38]. However, no inhibition measurement was demonstrated within this report, and the method relies on a complex equipment setup not presently suitable for testing a large number of small molecules.

Inhibitors of APE1 Nuclease Activities

APE1 is essential for animal viability, as deletion of both alleles leads to early stage embryonic lethality in mice [39], and more recent studies have indicated a vital role for this protein in human cell viability [40]. Approaches such as antisense and siRNA have demonstrated that reduced levels of APE1 protein increase the sensitivity of cells to DNA-damaging agents that generate BER substrates, e.g. oxidizing and alkylating compounds. However, in most cases,

whether the hypersensitivity results from impairment in its nuclease function(s) or one of its other roles has not been explicitly addressed. That said, recent work, which will not be described in detail herein, has begun to delineate the unique contributions of the nuclease and redox regulatory functions of APE1 in cell viability and stress resistance [41,42].

Several pre-clinical and clinical studies have validated APE1 as a rational anticancer drug target [43,44]. For instance, APE1 expression levels and/or subcellular localization has been found to be altered in several tumor types, and in some instances, is predictive of responsiveness to radio- or chemotherapy. In addition, studies have shown that reduced APE1 protein levels or impaired APE1 protein function increase cellular sensitivity to a range of direct and indirect DNA-interactive anticanceragents, including ionizing radiation, thiopeta, carmustine, temozolomide, and the antimetabolites troxacitabine and 5-fluorouracil [45–49]. This increased cellular sensitivity corresponds in many cases with elevated DNA damage, indicting the DNA metabolizing functions of the protein in resistance. Furthermore, as will be discussed next, many of the identified APE1 small molecule inhibitors, which were selected based on their ability to inhibit APE1 endonuclease activity, and thus, likely don't affect the other functions of APE1 (although this needs to be confirmed in most cases), have been shown to improve the efficacy of clinically relevant DNA-interactive drugs.

CRT0044876 (7-Nitro-indole-2 carboxylic acid)

Using the fluorescein/dabcyl-based AP site incision assay described above, Madhusudan *et al.* [33] identified the first biochemical and biological inhibitor of APE1 from a screen of a collection of structurally-diverse small molecules (5000 in total). The top compound, CRT0044876 (Figure 5), was shown to be a specific inhibitor of the *E. coli* exonuclease III family of AP endonucleases, which includes APE1, yet did not inhibit the repair activity of the structurally-distinct *E. coli* AP endonuclease, endonuclease IV (EndoIV). Moreover, at non-toxic doses, CRT0044876 was found to potentiate the cell killing effect of a number of DNA-damaging agents, including the laboratory chemical methyl methanesulfonate (MMS) and the clinically relevant alkylator temozolomide. CRT0044876 did not alter the cytotoxicity of agents that induced DNA damage not commonly repaired by BER, such as ultraviolet light, nitrogen mustard, and camptothecin, suggesting specificity for APE1 inhibition. However, since the initial report, the reproducibility of this compound has been brought into question [34,43], and the lack of analogues reported for this singleton complicates the interpretation of any enzymatic or cellular activity that CRT0044876 may possess. While the reason for the apparent discrepancy in results is unclear, it may stem from differences in reaction conditions, the source of the small molecule, or possibly the amino acid composition or status of the recombinant protein. Further studies to better clarify the inconsistencies are needed, as investigators are actively employing CRT0044876 to evaluate the utility of APE1 inhibition in clinically relevant treatment paradigms (see for instance [50,51]). It is also noteworthy that the nitro-aromatic feature of CRT0044876 is generally associated with toxicity issues [52], and may therefore limit the utility of this compound as a drug candidate.

Since CRT0044876 has poor drug-like properties including aqueous solubility and membrane permeability (i.e. sharp drop-off between biochemical and cellular potency), and thus, does not represent a suitable starting point for medicinal chemistry lead optimization, Madhusudan and colleagues have recently adopted a virtual screening strategy. In this approach, the CRT0044876 template, in addition to prototypical molecular scaffolds designed on the basis of the shape of the ligand binding site within APE1, have been used to perform a rapid structure-based similarity search of a large virtual library of drug-like molecules. 'Hits' from this search were subsequently subjected to the more computationally-costly process of docking-based evaluation, followed by detailed biochemical and cellular investigations. Several potent APE1

inhibitors have been isolated using this approach that appear to be promising hit to lead conversion candidates (Srinivasan Madhusudan, personal communication).

Arylstibonic acids

Since the compounds reported in the literature at the time, including CRT0044876, were generally weak (μM) inhibitors of APE1, Stivers and colleagues set out to identify more potent enzyme inactivators [53]. Using a standard fluorescein/dabcyl-based molecular beacon assay, they screened the 2000-compound NCI Diversity Set of small molecules and identified aromatic nitroso, carboxylate, sulfonamide, and arylstibonic acid compounds with μM affinities for the protein. Since arylstibonic acids appeared frequently as inhibitors of APE1 incision activity in the initial screen, and thus potentially represented a useful scaffold for further diversification, an additional 37-member arylstibonic acid library was tested. Notably, two compounds ("13755" and "13793"; Figure 5) were identified with IC_{50}s of 4 and 17 nM, respectively; neither appeared to be a non-specific inhibitor via binding DNA, as they were negative in a conventional dye-displacement assay. However, despite the potent, presumably direct, inhibition observed *in vitro*, none of the tested antimony-containing small molecules exhibited an obvious effect on the survival of cells challenged with MMS. Whether these compounds are simply not taken up by cells, or do not target APE1 *in vivo*, needs to be more clearly resolved, but one of the more potent arylstibonic acids (NSC-13755) did display a significant inhibitory effect on total AP endonuclease activity of whole cell extracts, suggesting some specificity for APE1 [34].

As discussed by Seiple and colleagues [53], the very small size of these inhibitors, combined with their relatively high potency, indicates that they largely owe their activity to the arylstibonic core, akin to phosphonate derivatives. As such, this entire class of compounds can be expected to inhibit additional nucleic acid-interacting enzymes [54], making it difficult to develop them into selective agents. Further complicating the picture is the uncertainty surrounding the whole-organ toxicity potential of antimony-containing compounds, particularly as related to the interconversion between their trivalent and pentavalent forms. That said, examples exist of the continuing use and optimization of arsenic- and antimony-based therapeutic agents, particularly in cases of acute infections and cancers associated with poor prognosis [55,56]. Whether such compounds can be modified in a way to direct specificity against APE1 is unclear.

Pharmacophore-guided inhibitors

Guided by the unique interactions of the APE1 active site with abasic DNA, Zawahir *et al.* [57] designed a set of pharmacophore models that were used to carry out a virtual screen of a 365,000 small molecule library. Identified hits were subsequently selected for further biochemical analysis based on pharmacophore fit value, pharmacophore mapping pattern, predicted binding orientation, and interactions of the compound within the APE1 active site. Employing a radiolabeled DNA substrate-based AP site incision assay, the authors found that the majority of inhibitors displayed IC_{50} values of ~ 3 to $20 \mu\text{M}$ against APE1, while showing no pronounced, non-specific inhibition of the unrelated AP endonuclease EndoIV or the general DNA phosphate backbone cleaving enzyme HIV-1 integrase. The most effective APE1 inhibitors maintained a structural platform that consisted of an optimum-sized central hydrophobic core linked to two negatively ionizable features, such as two carboxyl groups (see for instance compounds 1, 17, and 21 from the study; Figure 5). However, as will be discussed below, not all inhibitors of APE1 possess these features, ruling out the exclusivity of the suggested pharmacophore and indicating that additional stabilizing interactions beyond those afforded by two negatively-charged anchor points need to be considered during the design and optimization of direct APE1 inhibitors. Additional investigation of the top pharmacophore-based inhibitors, particularly to derive structure-activity relationship(s) and improve potency,

is also necessary to further advance the overall strategy presented by Zawahir and colleagues [57]. Lastly, it is important to note that the biological efficacy of the compounds identified in this effort has yet to be described.

6-hydroxy-DL-DOPA, Reactive blue 2, and myricetin

Since the reported effectiveness of CRT0044876 had come into question and since the biological value of the arylstibonic acids was not evident, Simeonov *et al.* [34] set out to identify novel APE1 inhibitors by screening the commercially available Library of Pharmacologically Active Compounds (LOPAC¹²⁸⁰), a collection of well-characterized, drug-like molecules representing all major target classes. Using a series of optimized screening and validation assays (including an EndoIV counterscreen and a dye-displacement test), three compounds were identified as selective, direct inhibitors of APE1 incision activity, i.e. 6-hydroxy-DL-DOPA, Reactive blue 2, and myricetin (Figure 5). Each of these bioactives was also found to enhance the cytotoxic and genotoxic potency of the alkylating agent MMS. However, 6-hydroxy-DL-DOPA, Reactive blue 2, and myricetin, which have well characterized pharmacological profiles, are known to have additional cellular targets (see discussion within [34]) and are not easily amendable to chemical modification. Moreover, 6-hydroxy-DL-DOPA and some of its analogues suffer from instability in the presence of oxygen. We note that Levodopa (i.e. L-DOPA), a naturally-occurring dietary supplement and psychoactive drug used in the clinical treatment of Parkinson's disease that maintains chemical features similar to 6-hydroxy-DL-DOPA, did not inhibit APE1 endonuclease activity in a conventional radiolabeled DNA substrate assay (unpublished observation).

Aurintricarboxylic Acid (ATA)

One of the most potent inhibitors of APE1 identified in the screen of the LOPAC¹²⁸⁰ (see above) was ATA [34], displaying an IC₅₀ value in the tens of nanomolar range (Figure 5). However, this compound appears to be a highly potent, pan-selective inhibitor of DNA- and RNA-processing enzymes [58], presumably due to its DNA-mimetic properties [59]. Thus, while ATA is a readily available compound that carries some utility as a control reagent, it is unattractive as a candidate agent for targeted combination therapy due to its promiscuity and therefore high probability for unpredictable off-target effects. Furthermore, ATA has been postulated to form a radical homopolymer in solution, casting doubt about its tractability. We stress that investigators should proceed with caution in ongoing and future screening efforts, as other compounds will likely be identified that are potent APE1 inhibitors simply due to DNA likeness, yet will turn out to be pan-selective inhibitors of nucleic acid-processing enzymes.

APE1 Repair Inhibitor 03 (AR03)

Employing a similar strategy to that outlined in Figure 4, Bapat *et al.* [60] screened a library of 60,000 diverse small molecules for APE1 endonuclease inhibitors. After eliminating strong DNA-binders and insoluble compounds, four molecules, designated AR01 (2-(4-(2,5-dimethyl-1H-pyrryl-1-yl)phenoxy)acetic acid), AR02 (4-(2,6,8-trimethylquinolin-4-ylamino)phenol), AR03 (2,4,9-trimethylbenzo [b][1,8] naphthyridin-5-amine) and AR06 (N-(3-chlorophenyl)-5,6-dihydro-4H-cyclopenta [d] isoxazole-3-carboxamide), were identified as the most promising of the chemically distinct inhibitors with IC₅₀ values of $\leq 10 \mu\text{M}$. Of these, AR03 (Figure 5) was (i) validated using a radiolabeled oligonucleotide substrate, (ii) shown to have little effect on *E. coli* EndoIV AP site incision activity, and (iii) found to inhibit total AP endonuclease activity of human whole cell extracts. Further characterization of AR03 demonstrated that this compound effectively kills cells at low micromolar concentrations (LD₅₀ value of $\sim 1 \mu\text{M}$), promotes the accumulation of AP sites in chromosomal DNA of human cells, and potentiates the cytotoxicity of MMS and temozolomide in SF767 glioblastoma cells.

While AR03 was argued to exhibit selectivity for APE1 and have potential therapeutic utility, its planar fused ring structure is similar to that of recognized DNA-binders, a fact partially corroborated by AR03's activity against Endo IV, and as such, may warrant additional profiling work. Also, given the micromolar IC₅₀ of this inhibitor, medicinal chemistry optimization will need to be performed in order to improve its potency and potentially enhance its selectivity. Nonetheless, AR03 does represent one of the better validated APE1 inhibitors to date.

Lucanthone

Lucanthone (a.k.a. Miracil D) is an orally administered small-molecule (a thioxanthene) that has been used in the treatment of human schistosomiasis. Its heterocyclic ring structure (Figure 5) resembles that of actinomycin D, and like actinomycin D, the compound binds to DNA and inhibits RNA synthesis in bacteria [61]. While lucanthone has structural and biochemical similarities to actinomycin D, it has no hematological or gastrointestinal toxicity at clinically tolerated doses, thus making it an attractive therapeutic compound.

In the 1970s, lucanthone was shown to act as a radiosensitizer of cancer cells [62], possibly through the inhibition of post-radiation repair or as an inhibitor of topoisomerase II [63,64]. Bases and colleagues [65] subsequently reported that exposure of cells to lucanthone resulted in an accumulation of abasic sites, implicating APE1 as a target of this small molecule. Luo and Kelley [66] soon thereafter demonstrated that lucanthone is a direct inhibitor of APE1 *in vitro* and enhances the cell killing effect of the drug temozolomide in culture. Part of the inhibitory effect of lucanthone is undoubtedly a result of its ability to intercalate into DNA [61], but some appears to stem from a direct interaction with the APE1 protein (Mamta Naidu, personal communication). Nevertheless, due to the fact that the cellular consequences of lucanthone occur at doses much lower than required to inhibit APE1 nuclease activities *in vitro*, it has been postulated that the effects of the small molecule are mediated through inhibition of topoisomerase II or another cellular protein. Since lucanthone is currently in clinical development for the treatment of brain tumors due to its ability to readily cross the blood brain barrier, further information regarding its mechanism of action, and in particular its possible cellular targets, are of great interest.

Methoxyamine

Methoxyamine (trademark TRC102) is small molecule that can be administered orally or intravenously, and is actively being pursued by TRACON Pharmaceuticals in Phase I clinical trials in the management of advanced cancers, such as malignant melanoma, primary brain tumors, and lung cancer (see further details at <http://www.traconpharma.com>). Methoxyamine forms a covalent alkoxyamine-adducted intermediate with the ring-open form of a deoxyribose residue, generating an AP site product that is refractory to APE1 cleavage, and hence, largely resistant to BER processing [67]. Thus, unlike the mechanism of action presumed for the molecules described earlier (Figure 5), methoxyamine is an indirect inhibitor of APE1, as it is not known to bind physically to the protein. A sizeable collection of pre-clinical data, largely from the Gerson laboratory, indicates that methoxyamine significantly enhances the antitumor effect of alkylating agents such as carmustine and temozolomide, further supporting the idea that inhibition of AP site repair (i.e. APE1) would be advantageous in certain cancer therapy protocols [68,69].

Departing Thoughts

Many of the agents used in the clinic today to eradicate or manage cancer are cytotoxins that kill rapidly dividing cells by introducing lethal genetic damage [70]. Past and recent evidence has indicated the potential benefit of inhibiting DNA repair pathways in treatment paradigms that involve such DNA-interactive drugs. There has in fact been a renewed and enhanced effort

to develop novel DNA repair inhibitors that may improve therapeutic agent efficacy, primarily due to the recent promising clinical results using inhibitors against the strand break response protein, PARP-1 [17,71,72]. APE1 is an attractive pharmaceutical target due to its central role in BER, and the evidence that APE1 repair activity correlates with anticancer agent resistance. Thus, a number of groups have recently set out to develop small molecules that inhibit APE1 endonuclease activity directly, although the design of a potent and selective biological APE1 inhibitor remains elusive to date. Furthermore, a “dominant-negative” form of APE1, which binds substrate DNA with high affinity, but doesn’t execute strand incision, consequently blocking the ensuing steps of BER, may have analogous utility in gene therapy modalities [49,73].

Despite the lack of a pharmaceutical quality APE1 inhibitor, the recent reports detailed above represent an important step in that direction. *In silico* modeling indicates that many of the small molecules (Figure 5), such as CRT0044876, 6-hydroxy-DL-DOPA, arylstibonic analogues and lucanthone, adhere in a similar manner to the hydrophobic pocket of APE1 (consisting of W280, F266 and L282) that forms the binding site for the abasic ring structure in the protein-DNA complex ([33,34,53] and unpublished observation). Indeed, all of these compounds share a relatively small size and an aromatic hydrophobic central core, and except for lucanthone, have a negative ionizable group, most frequently a carboxylate. Thus, most of the current APE1 inhibitors tend to resemble the nucleobase-phosphate unit of DNA (though exceptions have been noted, e.g. myricetin and lucanthone). It is conceivable that some degree of DNA “likeness” may need to be retained to achieve high potency. However, additional chemical features will also need to be present in order for the next-generation chemotypes to be APE1-selective. Structure-guided design for direct APE1 inhibitors should take into account not only the residues that define the abasic site binding pocket, but more distal features of the enzyme that are presumably responsible for recognition of the overall bend in DNA made possible by the abasic site [74,75].

Looking forward, it is evident that synthetic chemical design of analogs is necessary to create more powerful structure-activity relationship profiles, and ultimately, high-affinity selective compounds. In addition, characterization of the binding mode of one or more of the current inhibitors by X-ray crystallography would expedite the rational design of APE1 inhibitors with improved potency. Furthermore, experiments beyond simple potentiation of toxicity in cell culture are needed, such as extending the use of prioritized small molecules into relevant tissue or animal cancer models to explore possible side-effects and further validate APE1 as a pharmacological target for anticancer therapies. While it seems evident that we are at the early stages of direct APE1 inhibitor design and some time away from formal clinical trials, it is important to keep in mind that inhibition of BER is likely to be most advantageous when coupled with a relevant DNA-interactive drug, such as the alkylator temozolomide, commonly used in the treatment of brain cancers [76]. Of course there are additional considerations – such as delivery of the inhibitor to the site of the tumor and the utility of the current animal models as pre-clinical assessment tools – that fall outside the scope of this review.

It is worth pointing out that in addition to direct inhibitors of APE1 nuclease activities, inhibitors against the other functions of APE1 may prove clinically valuable as well. For example, inhibition of the REF-1 function of APE1 may be a novel therapeutic approach in the management of asthma and airway fibrosis [77], or an anti-proliferative or anti-angiogenesis strategy in the treatment of solid tumors [78,79]. A recent report by Tell and co-authors [21] described an interaction between APE1 and nucleophosmin 1 (NPM1), which appears to provide an additional mechanism for controlling the localization, substrate specificity, and activity of APE1. Thus, small molecule inhibitors of this interaction might serve as an alternative valuable modulator of the repair enzyme. The readers of this article are

encouraged to review the other manuscripts of this Special Issue, which touch upon several aspects of APE1 biochemistry/biology and DNA damage responses.

Acknowledgments

We thank Drs. Mamta Naidu (Brookhaven National Laboratory, USA) and Srinivasan Madhusudan (University of Nottingham, UK) for sharing unpublished observations and for constructive input on the manuscript. This work was supported by the Intramural Research Program of the National Institute on Aging, NIH; the Molecular Libraries Initiative of the NIH Roadmap for Medical Research; the Intramural Research Program of National Human Genome Research Institute, NIH; and grant 1 R03 MH086444-01 to DMWIII.

Reference List

1. Friedberg EC. A brief history of the DNA repair field. *Cell Res* 2008;18:3–7. [PubMed: 18157159]
2. Kelner A. Effect of Visible Light on the Recovery of *Streptomyces Griseus* Conidia from Ultra-violet Irradiation Injury. *Proc Natl Acad Sci U S A* 1949;35:73–79.
3. Dulbecco R. Reactivation of ultra-violet-inactivated bacteriophage by visible light. *Nature* 1949;163:949. [PubMed: 18229246]
4. Rupert CS. Enzymatic photoreactivation: overview. *Basic Life Sci* 1975;5A:73–87. [PubMed: 1103856]
5. Lindahl T. Instability and decay of the primary structure of DNA. *Nature* 1993;362:709–715. [PubMed: 8469282]
6. Loeb LA, Preston BD. Mutagenesis by apurinic/aprimidinic sites. *Annu Rev Genet* 1986;20:201–230. [PubMed: 3545059]
7. Kane CM, Linn S. Purification and characterization of an apurinic/aprimidinic endonuclease from HeLa cells. *J Biol Chem* 1981;256:3405–3414. [PubMed: 6259165]
8. Shaper NL, Grafstrom RH, Grossman L. Human placental apurinic/aprimidinic endonuclease. Its isolation and characterization. *J Biol Chem* 1982;257:13455–13458. [PubMed: 7142159]
9. Demple B, Herman T, Chen DS. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. *Proc Natl Acad Sci U S A* 1991;88:11450–11454. [PubMed: 1722334]
10. Robson CN, Hickson ID. Isolation of cDNA clones encoding a human apurinic/aprimidinic endonuclease that corrects DNA repair and mutagenesis defects in *E. coli* xth (exonuclease III) mutants. *Nucleic Acids Res* 1991;19:5519–5523. [PubMed: 1719477]
11. Seki S, Hatsushika M, Watanabe S, Akiyama K, Nagao K, Tsutsui K. cDNA cloning, sequencing, expression and possible domain structure of human APEX nuclease homologous to *Escherichia coli* exonuclease III. *Biochim Biophys Acta* 1992;1131:287–299. [PubMed: 1627644]
12. Mol CD, Hosfield DJ, Tainer JA. Abasic site recognition by two apurinic/aprimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means. *Mutat Res* 2000;460:211–229. [PubMed: 10946230]
13. Wilson DM III, Barsky D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. *Mutat Res* 2001;485:283–307. [PubMed: 11585362]
14. Demple B, Sung JS. Molecular and biological roles of Ape1 protein in mammalian base excision repair. *DNA Repair (Amst)* 2005;4:1442–1449. [PubMed: 16199212]
15. Bhakat KK, Mantha AK, Mitra S. Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. *Antioxid Redox Signal* 2009;11:621–638. [PubMed: 18715144]
16. Luo M, He H, Kelley MR, Georgiadis M. Redox Regulation of DNA Repair: Implications for Human Health and Cancer Therapeutic Development. *Antioxid Redox Signal*. 2009
17. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. *Nat Rev Cancer* 2008;8:193–204. [PubMed: 18256616]
18. Dlakic M. Functionally unrelated signalling proteins contain a fold similar to Mg²⁺-dependent endonucleases. *Trends Biochem Sci* 2000;25:272–273. [PubMed: 10838565]

19. Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. *EMBO J* 2001;20:6530–6539. [PubMed: 11707423]
20. Wong HK, Muftuoglu M, Beck G, Imam SZ, Bohr VA, Wilson DM III. Cockayne syndrome B protein stimulates apurinic endonuclease 1 activity and protects against agents that introduce base excision repair intermediates. *Nucleic Acids Res* 2007;35:4103–4113. [PubMed: 17567611]
21. Vascotto C, Fantini D, Romanello M, Cesaratto L, Deganuto M, Leonardi A, Radicella JP, Kelley MR, D'Ambrosio C, Scaloni A, Quadrioglio F, Tell G. APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. *Mol Cell Biol* 2009;29:1834–1854. [PubMed: 19188445]
22. Chen DS, Herman T, Demple B. Two distinct human DNA diesterases that hydrolyze 3'-blocking deoxyribose fragments from oxidized DNA. *Nucleic Acids Res* 1991;19:5907–5914. [PubMed: 1719484]
23. Wilson DM III, Takeshita M, Grollman AP, Demple B. Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA. *J Biol Chem* 1995;270:16002–16007. [PubMed: 7608159]
24. Suh D, Wilson DM III, Povirk LF. 3'-phosphodiesterase activity of human apurinic/aprimidinic endonuclease at DNA double-strand break ends. *Nucleic Acids Res* 1997;25:2495–2500. [PubMed: 9171104]
25. Hadi MZ, Ginalski K, Nguyen LH, Wilson DM III. Determinants in nuclease specificity of Ape1 and Ape2, human homologues of *Escherichia coli* exonuclease III. *J Mol Biol* 2002;316:853–866. [PubMed: 11866537]
26. Chou KM, Cheng YC. An exonucleolytic activity of human apurinic/aprimidinic endonuclease on 3' mispaired DNA. *Nature* 2002;415:655–659. [PubMed: 11832948]
27. Chou KM, Kukhanova M, Cheng YC. A novel action of human apurinic/aprimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA. *J Biol Chem* 2000;275:31009–31015. [PubMed: 10906132]
28. Chou KM, Cheng YC. The exonuclease activity of human apurinic/aprimidinic endonuclease (APE1). Biochemical properties and inhibition by the natural dinucleotide Gp4G. *J Biol Chem* 2003;278:18289–18296. [PubMed: 12624104]
29. Wilson DM III. Properties of and substrate determinants for the exonuclease activity of human apurinic endonuclease Ape1. *J Mol Biol* 2003;330:1027–1037. [PubMed: 12860125]
30. Gros L, Ishchenko AA, Ide H, Elder RH, Saparbaev MK. The major human AP endonuclease (Ape1) is involved in the nucleotide incision repair pathway. *Nucleic Acids Res* 2004;32:73–81. [PubMed: 14704345]
31. Berquist BR, McNeill DR, Wilson DM III. Characterization of abasic endonuclease activity of human Ape1 on alternative substrates, as well as effects of ATP and sequence context on AP site incision. *J Mol Biol* 2008;379:17–27. [PubMed: 18439621]
32. Barnes T, Kim WC, Mantha AK, Kim SE, Izumi T, Mitra S, Lee CH. Identification of Apurinic/aprimidinic endonuclease 1 (APE1) as the endonuclease that cleaves c-myc mRNA. *Nucleic Acids Res* 2009;37:3946–3958. [PubMed: 19401441]
33. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, Talbot DC, Hammonds T, Freemont PA, Sternberg MJ, Dianov GL, Hickson ID. Isolation of a small molecule inhibitor of DNA base excision repair. *Nucleic Acids Res* 2005;33:4711–4724. [PubMed: 16113242]
34. Simeonov A, Kulkarni A, Dorjsuren D, Jadhav A, Shen M, McNeill DR, Austin CP, Wilson DM III. Identification and characterization of inhibitors of human apurinic/aprimidinic endonuclease APE1. *PLoS One* 2009;4:e5740. [PubMed: 19484131]
35. Dorjsuren D, Wilson DM III, Beard WA, McDonald JP, Austin CP, Woodgate R, Wilson SH, Simeonov A. A real-time fluorescence method for enzymatic characterization of specialized human DNA polymerases. *Nucleic Acids Res* 2009;37:e128. [PubMed: 19684079]
36. Chen X, Ballin JD, la-Maria J, Tsai MS, White EJ, Tomkinson AE, Wilson GM. Distinct kinetics of human DNA ligases I, IIIalpha, IIIbeta, and IV reveal direct DNA sensing ability and differential physiological functions in DNA repair. *DNA Repair (Amst)* 2009;8:961–968. [PubMed: 19589734]

37. Choudhary S, Sommers JA, Brosh RM Jr. Biochemical and kinetic characterization of the DNA helicase and exonuclease activities of werner syndrome protein. *J Biol Chem* 2004;279:34603–34613. [PubMed: 15187093]
38. Lee W, Lee YI, Lee J, Davis LM, Deininger P, Soper SA. Cross-talk-free dual-color fluorescence cross-correlation spectroscopy for the study of enzyme activity. *Anal Chem* 2010;82:1401–1410. [PubMed: 20073480]
39. Xanthoudakis S, Smeyne RJ, Wallace JD, Curran T. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. *Proc Natl Acad Sci U S A* 1996;93:8919–8923. [PubMed: 8799128]
40. Fung H, Demple B. A vital role for ape1/ref1 protein in repairing spontaneous DNA damage in human cells. *Mol Cell* 2005;17:463–470. [PubMed: 15694346]
41. Izumi T, Brown DB, Naidu CV, Bhakat KK, MacInnes MA, Saito H, Chen DJ, Mitra S. Two essential but distinct functions of the mammalian abasic endonuclease. *Proc Natl Acad Sci U S A* 2005;102:5739–5743. [PubMed: 15824325]
42. Jiang Y, Guo C, Fishel ML, Wang ZY, Vasko MR, Kelley MR. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. *DNA Repair (Amst)* 2009;8:1273–1282. [PubMed: 19726241]
43. Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. *Mol Aspects Med* 2007;28:375–395. [PubMed: 17560642]
44. Abbotts R, Madhusudan S. Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancer. *Cancer Treat Rev.* 2010
45. Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB, Kolstoe DD. The apurinic/aprimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. *Clin Cancer Res* 2002;8:3008–3018. [PubMed: 12231548]
46. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. *Mol Cancer Ther* 2004;3:679–686. [PubMed: 15210853]
47. Bobola MS, Finn LS, Ellenbogen RG, Geyer JR, Berger MS, Braga JM, Meade EH, Gross ME, Silber JR. Apurinic/aprimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. *Clin Cancer Res* 2005;11:7405–7414. [PubMed: 16243814]
48. Lam W, Park SY, Leung CH, Cheng YC. Apurinic/aprimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine). *Mol Pharmacol* 2006;69:1607–1614. [PubMed: 16481390]
49. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM III. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. *Mol Cancer Res* 2009;7:897–906. [PubMed: 19470598]
50. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. *Mol Cancer Ther* 2008;7:1985–1992. [PubMed: 18645008]
51. Seo Y, Kinsella TJ. Essential role of DNA base excision repair on survival in an acidic tumor microenvironment. *Cancer Res* 2009;69:7285–7293. [PubMed: 19723658]
52. Toxicity of Nitroaromatic Compounds. Hemisphere Publishing Corporation; 1985.
53. Seiple LA, Cardellina JH, Akee R, Stivers JT. Potent inhibition of human apurinic/aprimidinic endonuclease 1 by arylstibonic acids. *Mol Pharmacol* 2008;73:669–677. [PubMed: 18042731]
54. Kim H, Cardellina JH, Akee R, Champoux JJ, Stivers JT. Arylstibonic acids: novel inhibitors and activators of human topoisomerase IB. *Bioorg Chem* 2008;36:190–197. [PubMed: 18508107]
55. Frezard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. *Molecules* 2009;14:2317–2336. [PubMed: 19633606]

56. Sharma P, Perez D, Cabrera A, Rosas N, Arias JL. Perspectives of antimony compounds in oncology. *Acta Pharmacol Sin* 2008;29:881–890. [PubMed: 18664320]
57. Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. *J Med Chem* 2009;52:20–32. [PubMed: 19072053]
58. Bina-Stein M, Tritton TR. Aurintricarboxylic acid is a nonspecific enzyme inhibitor. *Mol Pharmacol* 1976;12:191–193. [PubMed: 1256444]
59. Gonzalez RG, Haxo RS, Schleich T. Mechanism of action of polymeric aurintricarboxylic acid, a potent inhibitor of protein--nucleic acid interactions. *Biochemistry* 1980;19:4299–4303. [PubMed: 6158332]
60. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, Kelley MR. Novel small molecule inhibitor of Ape1 endonuclease blocks proliferation and reduces viability of glioblastoma cells. *J Pharmacol Exp Ther*. 2010
61. Hirschberg E, Weinstein IB, Gersten N, Marner E, Finkelstein T, Carchman R. Structure-activity studies on the mechanism of action of miracil D. *Cancer Res* 1968;28:601–607. [PubMed: 4966649]
62. Bases R. Enhancement of x-ray damage in HeLa cells by exposure to lucanthone (Miracil D) following radiation. *Cancer Res* 1970;30:2007–2011. [PubMed: 5456085]
63. Bases R, Leifer A, Rozycki H, Blake C Jr, Neubort S. Effects of lucanthone on the sedimentation properties of DNA from HeLa cells. *Cancer Res* 1977;37:2177–2181. [PubMed: 861944]
64. Bases RE, Mendez F. Topoisomerase inhibition by lucanthone, an adjuvant in radiation therapy. *Int J Radiat Oncol Biol Phys* 1997;37:1133–1137. [PubMed: 9169823]
65. Mendez F, Goldman JD, Bases RE. Abasic sites in DNA of HeLa cells induced by lucanthone. *Cancer Invest* 2002;20:983–991. [PubMed: 12449731]
66. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. *Anticancer Res* 2004;24:2127–2134. [PubMed: 15330152]
67. Rosa S, Fortini P, Karran P, Bignami M, Dogliotti E. Processing in vitro of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed in vivo. *Nucleic Acids Res* 1991;19:5569–5574. [PubMed: 1719478]
68. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. *Curr Opin Investig Drugs* 2004;5:623–627.
69. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. *Clin Cancer Res* 2007;13:260–267. [PubMed: 17200364]
70. Thurston, DE. *Chemistry and Pharmacology of Anticancer Drugs*. CRC Press, Taylor and Francis Group, LLC; Boca Raton, FL: 2007.
71. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. *Br Med Bull* 2009;89:23–40. [PubMed: 19208614]
72. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. *Eur J Cancer* 2010;46:9–20. [PubMed: 19926276]
73. McNeill DR, Wilson DM III. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. *Mol Cancer Res* 2007;5:61–70. [PubMed: 17259346]
74. Barsky D, Foloppe N, Ahmadi S, Wilson DM III, MacKerell AD Jr. New insights into the structure of abasic DNA from molecular dynamics simulations. *Nucleic Acids Res* 2000;28:2613–2626. [PubMed: 10871413]
75. Mol CD, Izumi T, Mitra S, Tainer JA. DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination. *Nature* 2000;403:451–456. [PubMed: 10667800]
76. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. *Cancer Chemother Pharmacol* 2009;64:647–655. [PubMed: 19543728]
77. Nguyen C, Teo JL, Matsuda A, Eguchi M, Chi EY, Henderson WR Jr, Kahn M. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. *Proc Natl Acad Sci U S A* 2003;100:1169–1173. [PubMed: 12552119]

78. Luo M, Delaplane S, Jiang A, Reed A, He Y, Fishel M, Nyland RL, Borch RF, Qiao X, Georgiadis MM, Kelley MR. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. *Antioxid Redox Signal* 2008;10:1853–1867. [PubMed: 18627350]
79. Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. *J Cell Physiol* 2009;219:209–218. [PubMed: 19097035]
80. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. *Cell Res* 2008;18:27–47. [PubMed: 18166975]
81. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: Base excision repair: the long and short of it. *Cell Mol Life Sci* 2009;66:981–993. [PubMed: 19153658]
82. Almeida KH, Sobol RW. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. *DNA Repair (Amst)* 2007;6:695–711. [PubMed: 17337257]
83. Wilde JA, Bolton PH, Masumder A, Manoharan M, Gerlt JA. Characterization of the equilibrating forms of the aldehydic abasic site in duplex DNA by ¹⁷O NMR. *J Amer Chem Soc* 1989;111:1894–1896.
84. Gorman MA, Morera S, Rothwell DG, de La FE, Mol CD, Tainer JA, Hickson ID, Freemont PS. The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. *EMBO J* 1997;16:6548–6558. [PubMed: 9351835]
85. Mundle ST, Delaney JC, Essigmann JM, Strauss PR. Enzymatic mechanism of human apurinic/apyrimidinic endonuclease against a THF AP site model substrate. *Biochemistry* 2009;48:19–26. [PubMed: 19123919]
86. Erzberger JP, Wilson DM III. The role of Mg²⁺ and specific amino acid residues in the catalytic reaction of the major human abasic endonuclease: new insights from EDTA-resistant incision of acyclic abasic site analogs and site-directed mutagenesis. *J Mol Biol* 1999;290:447–457. [PubMed: 10390343]
87. Lowry DF, Hoyt DW, Khazi FA, Bagu J, Lindsey AG, Wilson DM III. Investigation of the role of the histidine-aspartate pair in the human exonuclease III-like abasic endonuclease, Ape1. *J Mol Biol* 2003;329:311–322. [PubMed: 12758078]
88. Mundle ST, Fattal MH, Melo LF, Coriolan JD, O'Regan NE, Strauss PR. Novel role of tyrosine in catalysis by human AP endonuclease 1. *DNA Repair (Amst)* 2004;3:1447–1455. [PubMed: 15380100]
89. Lipton AS, Heck RW, Primak S, McNeill DR, Wilson DM III, Ellis PD. Characterization of Mg²⁺ binding to the DNA repair protein apurinic/apyrimidinic endonuclease 1 via solid-state ²⁵Mg NMR spectroscopy. *J Am Chem Soc* 2008;130:9332–9341. [PubMed: 18576638]
90. Wilson DM III. Processing of nonconventional DNA strand break ends. *Environ Mol Mutagen* 2007;48:772–782. [PubMed: 17948279]
91. Takeshita M, Chang CN, Johnson F, Will S, Grollman AP. Oligodeoxynucleotides containing synthetic abasic sites. Model substrates for DNA polymerases and apurinic/apyrimidinic endonucleases. *J Biol Chem* 1987;262:10171–10179. [PubMed: 2440861]

Figure 1.

The Base Excision Repair Response. Indicated to the left are the five major enzymatic steps of short-patch BER. Other sub-pathways of BER exist (e.g. long-patch), and are described in greater detail elsewhere [80,81]. Typically, BER is initiated by removal of a damaged or inappropriate base (denoted by yellow star) through the action of a DNA glycosylase, which hydrolyzes the N-glycosidic bond that links the base to the sugar-phosphate backbone, generating an AP site. APE1, the major mammalian AP endonuclease, then cleaves the DNA backbone immediately 5' to the abasic lesion. The subsequent steps of BER – gap-filling to replace the missing nucleotide, removal of the 5'-deoxyribose phosphate (dRP), and sealing of the final nick – are performed primarily by DNA polymerase β and a complex of XRCC1 and DNA ligase 3 α , although back-up mechanisms exist [82]. As amplified within the red circle, the hydrolytic 2'-deoxyribose AP site exists primarily (at ~99%) in a ring-closed form (left), in one of two racemic hemiacetal arrangements, α or β , which are in an equilibrium mixture. Reduction of the ring-closed AP site can produce a ring-opened aldehyde form (middle). This ring-opened form is susceptible to hydration, generating a hydrated aldehyde AP site (right) ([83] and references therein).

Figure 2.

APE1 Primary Sequence Conservation and 3-Dimensional Structure. Shown (top) is a linear, schematic comparison of the human APE1 and *E. coli* exonuclease III (*Xth*) proteins. Indicated are the conserved catalytic residues: E96, D210, D283 and H309 in APE1. The nuclear targeting region (shaded portion, NLS), the acetylation sites (K6 and K7, dashed line), and a critical redox regulatory cysteine residue (C65) is denoted within the unique N-terminal portion of the human protein [15,16]. The amino acid length of the two proteins is indicated to the right in italics. Below is a ribbon diagram of the human APE1 protein. β -strands are shown in cyan and α -helices in red, with the four-layered α/β sandwich fold apparent. The proposed major groove DNA recognition loop, $\alpha.8$, is denoted, as is the minor groove recognition loop, $\alpha.11$. Coordinates were from 1BIX [84].

Figure 3.

APE1 Catalytic Reaction Mechanism and 3'-Damage Substrates. In the reaction shown (left), H309 acts as the general base and abstracts a proton from a water molecule to generate the active site nucleophile [85]. D283 forms a hydrogen bond with H309 to help stabilize the positive charge that develops upon proton abstraction. The metal ion bound by E96 interacts with the negatively charged phosphate group and aids in nucleophilic attack by the hydroxyl, and in one model, also serves to stabilize the leaving group [84]. Alternatively, D210, whose pKa is potentially altered by extensive hydrogen bonding, plays the role of the Lewis base and protonates the 3' leaving group [86]. Additional reaction mechanisms have been proposed, but are not depicted or described herein [75,87–89]. Shown to the right are 3'-damage substrates of APE1. Oxidation of C-4' results in fragmentation of the deoxyribose, causing strand breakage and the formation of a 3'-phosphoglycolate ester or a 3'-phosphate; 3'-phosphate groups can also be generated by bifunctional DNA glycosylases [90]. The α,β -unsaturated aldehyde is the β -elimination product of a bifunctional DNA glycosylase. Troxacitabine is an L-stereoisomeric, chain-terminating nucleoside analog that is a primary substrate for APE1 excision activity [27].

Figure 4.

APE1 Screening Assay Principle. A deoxyoligonucleotide containing an internal tetrahydrofuran abasic site analog [91] and a 5' fluorophore is annealed to a complementary strand with a 3' quencher to create a double-stranded DNA substrate. The close proximity of the fluorophore and the quencher results in a dampened signal upon light excitation. Following DNA backbone cleavage by APE1, a short deoxyoligonucleotide fluorophore-labeled product (typically around 4 to 6 nucleotides) is spontaneously released from the remaining DNA fragment possessing the quencher, causing the fluorophore emission to increase. F can be any fluorophore, and Q represents any compatible quench moiety. The APE1 incision site is indicated by the arrow. The right side of the duplex is not complete, as denoted by the squiggly lines.

Figure 5. Identified Inhibitors of APE1 Endonuclease Activity. Shown are the identifiers, chemical features, and concentrations of compound reported to inhibit 50% of APE1 incision activity *in vitro* (parentheses). IC_{50} s were obtained from the following articles, [33,34,53,57,60,66], and compound “1”, “17” and “21” are described in [57].